Genix Pharmaceuticals Closes Private Placement
Genix Pharmaceuticals (TSXV: GENX) has completed a non-brokered private placement, raising $100,000 through the issuance of 2,000,000 units at $0.10 per unit. Each unit comprises one common share and one transferable warrant, with warrants exercisable at $0.10 per share until September 04, 2027.
The placement was entirely subscribed by company insiders - the President and CEO. The proceeds will be used for general working capital and potential new product funding. All securities issued are subject to a four-month hold period, and the offering completion remains subject to TSX Venture Exchange approval.
Genix Pharmaceuticals (TSXV: GENX) ha completato un collocamento privato senza broker, raccogliendo $100.000 tramite l’emissione di 2.000.000 di unità a $0,10 ciascuna. Ogni unità comprende una azione comune e una warrant trasferibile; le warrant sono esercitabili a $0,10 per azione fino al 04 settembre 2027.
Il collocamento è stato sottoscritto interamente da dirigenti della società — il Presidente e Amministratore Delegato. I proventi saranno utilizzati per il capitale circolante generale e per il possibile finanziamento di nuovi prodotti. Tutti i titoli emessi sono soggetti a un periodo di lock-up di quattro mesi e il completamento dell’offerta resta subordinato all’approvazione della TSX Venture Exchange.
Genix Pharmaceuticals (TSXV: GENX) ha completado una colocación privada sin corredor, recaudando $100,000 mediante la emisión de 2,000,000 de unidades a $0.10 por unidad. Cada unidad consta de una acción común y una garantía transferible; las garantías son ejercitables a $0.10 por acción hasta el 04 de septiembre de 2027.
La colocación fue suscrita en su totalidad por insiders de la compañía — el Presidente y CEO. Los fondos se destinarán a capital de trabajo general y a posibles financiaciones de nuevos productos. Todos los valores emitidos están sujetos a un periodo de retención de cuatro meses y la finalización de la oferta está sujeta a la aprobación de la TSX Venture Exchange.
Genix Pharmaceuticals (TSXV: GENX)는 중개인 없이 진행한 사모 발행을 완료하여, 주당 $0.10로 2,000,000 단위를 발행하여 $100,000를 조달했습니다. 각 단위는 보통주 1주와 양도 가능한 워런트 1개로 구성되며, 워런트는 2027년 9월 4일까지 주당 $0.10에 행사할 수 있습니다.
이번 발행은 회사 내부자(사장 겸 CEO)가 전액 인수했으며, 수익금은 일반 운전자본 및 잠재적 신제품 자금으로 사용될 예정입니다. 발행된 모든 증권은 4개월 보유 기간이 적용되며, 본 오퍼링의 완료는 TSX 벤처 거래소의 승인 대상입니다.
Genix Pharmaceuticals (TSXV: GENX) a réalisé un placement privé sans courtier, levant 100 000 $ par l’émission de 2 000 000 d’unités à 0,10 $ l’unité. Chaque unité comprend une action ordinaire et un warrant transférable; les warrants sont exerçables à 0,10 $ par action jusqu’au 04 septembre 2027.
Le placement a été intégralement souscrit par des initiés de la société — le président et le CEO. Les fonds serviront au fonds de roulement général et au financement éventuel de nouveaux produits. Tous les titres émis sont soumis à une période de blocage de quatre mois et la réalisation de l’offre est soumise à l’approbation de la TSX Venture Exchange.
Genix Pharmaceuticals (TSXV: GENX) hat eine nicht vermittelte Privatplatzierung abgeschlossen und $100.000 durch die Ausgabe von 2.000.000 Einheiten zu je $0,10 pro Einheit aufgenommen. Jede Einheit besteht aus einer Stammaktie und einer übertragbaren Wandelanleihe (Warrant); die Warrants sind bis zum 04. September 2027 zu $0,10 je Aktie ausübbar.
Die Platzierung wurde vollständig von Unternehmensinsidern — dem Präsidenten und CEO — gezeichnet. Die Erlöse werden für die allgemeine Betriebsmittelversorgung und mögliche Finanzierung neuer Produkte verwendet. Alle ausgegebenen Wertpapiere unterliegen einer Viermonats-Sperrfrist, und der Abschluss des Angebots steht unter dem Vorbehalt der Genehmigung durch die TSX Venture Exchange.
- None.
- 100% insider subscription may indicate limited external investor interest
- Small offering size of only $100,000 might not be sufficient for significant growth initiatives
- Dilutive effect on existing shareholders
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces that it has closed its previously announced non-brokered private placement raising gross proceeds of
The Company has issued 2,000,000 units (each a "Unit") at a price of
The private placement was subscribed to by two insiders of the Company, being the President and Chief Executive Officer.
The proceeds raised from the sale of the Units will be used for general working capital and potential funding for new products.
All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance. Completion of the Offering remains subject to the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.
Mr. Mahmoud S. Aziz, President & director and Mr. Sina Pirooz, CEO & director participated in the private placement and acquired an aggregate of 2,000,000 units for
The offered securities will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States or to or for the account or benefit of U.S. persons, except in certain transactions exempt from the registration requirements of the U.S. Securities Act. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities of the Company in the United States.
About Genix
Genix Pharmaceuticals Corporation is a highly innovative Canadian ophthalmic drug company focused on the research, development, manufacture, licensing and sales of novel and innovative prescription and over-the-counter ophthalmological products. The Company is committed to addressing the growing global demand for advanced eye-care solutions that improve health and quality of life.
On Behalf of the Board of Directors,
Mr. Mahmoud S. Aziz, President, Director
Genix Pharmaceuticals Corporation
www.genixpharm.com
For more information regarding Genix Pharmaceuticals Corporation, please contact:
Kevin Bottomley, Director
Tel: +1.604.609.6199
kbottomley@genixpharm.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward‐looking statements". Forward‐looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265168
FAQ
How much did Genix Pharmaceuticals (GENX) raise in its private placement?
Who participated in Genix Pharmaceuticals' September 2025 private placement?
What are the terms of GENX's warrant offering in the September 2025 placement?
How will Genix Pharmaceuticals use the proceeds from the private placement?
What is the hold period for securities issued in GENX's private placement?
